Prediction of adverse events in patients receiving rapid rituximab infusion: validation of a predictive model.

Rapid rituximab infusion was approved as treatment for non-Hodgkin lymphoma by the U.S. Food and Drug Administration in 2012, but it has been administered clinically since approval of the drug rituximab in 1997.